

Lei Yu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2913656/publications.pdf>

Version: 2024-02-01

52
papers

1,196
citations

471509

17
h-index

434195

31
g-index

55
all docs

55
docs citations

55
times ranked

1975
citing authors

#	ARTICLE	IF	CITATIONS
1	Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2017, 10, 151.	17.0	88
2	Investigation of the roles of exosomes in colorectal cancer liver metastasis. <i>Oncology Reports</i> , 2015, 33, 2445-2453.	2.6	78
3	On-Demand Drug Release from Dual-Targeting Small Nanoparticles Triggered by High-Intensity Focused Ultrasound Enhanced Glioblastoma-Targeting Therapy. <i>ACS Applied Materials & Interfaces</i> , 2017, 9, 31612-31625.	8.0	75
4	Tumor-penetrating Peptide Conjugated and Doxorubicin Loaded T ₁ -T ₂ Dual Mode MRI Contrast Agents Nanoparticles for Tumor Theranostics. <i>Theranostics</i> , 2018, 8, 92-108.	10.0	69
5	Precise glioblastoma targeting by AS1411 aptamer-functionalized poly (l- ¹³ -glutamylglutamine)-paclitaxel nanoconjugates. <i>Journal of Colloid and Interface Science</i> , 2017, 490, 783-796.	9.4	66
6	CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. <i>Journal of Hematology and Oncology</i> , 2021, 14, 82.	17.0	63
7	Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden. <i>Journal of Immunotherapy</i> , 2020, 43, 32-37.	2.4	56
8	Tandem Autologous Transplantation and Combined Infusion of CD19 and Bcma-Specific Chimeric Antigen Receptor T Cells for High Risk MM: Initial Safety and Efficacy Report from a Clinical Pilot Study. <i>Blood</i> , 2018, 132, 1009-1009.	1.4	47
9	Erythrocyte Membrane-Wrapped pH Sensitive Polymeric Nanoparticles for Non-Small Cell Lung Cancer Therapy. <i>Bioconjugate Chemistry</i> , 2017, 28, 2591-2598.	3.6	46
10	Liver-Targeted siRNA Lipid Nanoparticles Treat Hepatic Cirrhosis by Dual Antifibrotic and Anti-inflammatory Activities. <i>ACS Nano</i> , 2020, 14, 6305-6322.	14.6	45
11	Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytes. <i>Experimental Hematology and Oncology</i> , 2020, 9, 11.	5.0	43
12	pPB Peptide-Mediated siRNA-Loaded Stable Nucleic Acid Lipid Nanoparticles on Targeting Therapy of Hepatic Fibrosis. <i>Molecular Pharmaceutics</i> , 2018, 15, 53-62.	4.6	37
13	Hepatic macrophage targeted siRNA lipid nanoparticles treat non-alcoholic steatohepatitis. <i>Journal of Controlled Release</i> , 2022, 343, 175-186.	9.9	37
14	Nanoengineered Neutrophils as a Cellular Sonosensitizer for Visual Sonodynamic Therapy of Malignant Tumors. <i>Advanced Materials</i> , 2022, 34, e2109969.	21.0	32
15	Cholesterol Esterification Enzyme Inhibition Enhances Antitumor Effects of Human Chimeric Antigen Receptors Modified T Cells. <i>Journal of Immunotherapy</i> , 2018, 41, 45-52.	2.4	23
16	Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem cell transplantation for high-risk newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2022, 97, 537-547.	4.1	23
17	Nanocrystal Technology as a Strategy to Improve Drug Bioavailability and Antitumor Efficacy for the Cancer Treatment. <i>Current Pharmaceutical Design</i> , 2018, 24, 2416-2424.	1.9	21
18	Characterization of novel dual tandem CD19/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma. <i>Biomarker Research</i> , 2020, 8, 14.	6.8	21

#	ARTICLE	IF	CITATIONS
19	Cytotoxic effect of CLL-1 CAR-T cell immunotherapy with PD-1 silencing on relapsed/refractory acute myeloid leukemia. <i>Molecular Medicine Reports</i> , 2021, 23, .	2.4	20
20	Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients. <i>Cell Death and Disease</i> , 2020, 11, 207.	6.3	19
21	ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft. <i>Biomedicine and Pharmacotherapy</i> , 2021, 137, 111339.	5.6	19
22	Feasibility study of ⁶⁸ Ga-labeled CAR-T cells for in vivo tracking using micro-positron emission tomography imaging. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 824-831.	6.1	18
23	The differential effects of tumor burdens on predicting the net benefits of ssCART-19 cell treatment on r/r B-ALL patients. <i>Scientific Reports</i> , 2022, 12, 378.	3.3	18
24	Successful application of anti-CD19 CAR-T therapy with IL-6 knocking down to patients with central nervous system B-cell acute lymphocytic leukemia. <i>Translational Oncology</i> , 2020, 13, 100838.	3.7	15
25	Self-Assembled Tumor-Penetrating Peptide-Modified Poly(L- ¹³ -glutamylglutamine)-Paclitaxel Nanoparticles Based on Hydrophobic Interaction for the Treatment of Glioblastoma. <i>Bioconjugate Chemistry</i> , 2017, 28, 2823-2831.	3.6	14
26	Comparison of CAR-T19 and autologous stem cell transplantation for refractory/relapsed non-Hodgkin's lymphoma. <i>JCI Insight</i> , 2019, 4, .	5.0	14
27	Inhibition of Cholesterol Esterification Enzyme Enhances the Potency of Human Chimeric Antigen Receptor T Cells against Pancreatic Carcinoma. <i>Molecular Therapy - Oncolytics</i> , 2020, 16, 262-271.	4.4	12
28	Emerging role of RNA interference in immune cells engineering and its therapeutic synergism in immunotherapy. <i>British Journal of Pharmacology</i> , 2021, 178, 1741-1755.	5.4	12
29	Feasibility study of a novel preparation strategy for anti-CD7 CAR-T cells with a recombinant anti-CD7 blocking antibody. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 719-728.	4.4	12
30	FVIIa prevents the progressive hemorrhaging of a brain contusion by protecting microvessels via formation of the TF-FVIIa-FXa complex. <i>Neuroscience</i> , 2017, 348, 114-125.	2.3	11
31	A Novel Gd-DTPA-conjugated Poly(L- ¹³ -glutamyl-glutamine)-paclitaxel Polymeric Delivery System for Tumor Theranostics. <i>Scientific Reports</i> , 2017, 7, 3799.	3.3	11
32	Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-ALL Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 2311-2317.	2.0	11
33	Case Report: Reversible Neurotoxicity and a Clinical Response Induced by BCMA-Directed Chimeric Antigen Receptor T Cells Against Multiple Myeloma With Central Nervous System Involvement. <i>Frontiers in Immunology</i> , 2021, 12, 552429.	4.8	10
34	Donor origin CAR19 T cell infusion for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation. <i>Hematological Oncology</i> , 2019, 37, 655-658.	1.7	9
35	Ruxolitinib reduces severe CRS response by suspending CAR-T cell function instead of damaging CAR-T cells. <i>Biochemical and Biophysical Research Communications</i> , 2022, 595, 54-61.	2.1	9
36	Poly(L- ¹³ -glutamylglutamine) Polymer Enhances Doxorubicin Accumulation in Multidrug Resistant Breast Cancer Cells. <i>Molecules</i> , 2016, 21, 720.	3.8	8

#	ARTICLE	IF	CITATIONS
37	Hydrotropic polymer-based paclitaxel-loaded self-assembled nanoparticles: preparation and biological evaluation. <i>RSC Advances</i> , 2017, 7, 33248-33256.	3.6	8
38	Combined Infusion of Anti-CD19 and Anti-Bcma CART Cells after Early or Later Transplantation in the Front Line Was Superior to Salvage Therapy for High Risk MM. <i>Blood</i> , 2019, 134, 1949-1949.	1.4	8
39	Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cells. <i>Journal of Hematology and Oncology</i> , 2022, 15, 39.	17.0	8
40	CAR T cells equipped with a fully human scFv targeting Trop2 can be used to treat pancreatic cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2261-2274.	2.5	8
41	Decitabine may improve CAR-T efficacy in refractory/relapsed acute leukemia patients carrying TP53 alterations. <i>Bone Marrow Transplantation</i> , 2021, 56, 1710-1713.	2.4	7
42	Synthesis and biological evaluation of an anticancer drug delivery system: Poly(l- ¹³ -glutamyl-l-carbocysteine)-paclitaxel nanoconjugate. <i>Materials Science and Engineering C</i> , 2017, 81, 113-119.	7.3	7
43	Successful treatment of two relapsed/refractory t(8;21) acute myeloid leukemia patients by CD19-directed chimeric antigen receptor T cells. <i>Bone Marrow Transplantation</i> , 2019, 54, 1138-1140.	2.4	6
44	Gene Therapy for Hepatocellular Carcinoma Using Adenoviral Vectors Delivering a Gene Encoding IL-17A-Neutralizing Antibody Fragments. <i>Human Gene Therapy</i> , 2020, 31, 1074-1085.	2.7	6
45	A Photopolymerized Semi-Interpenetrating Polymer Networks-Based Hydrogel Incorporated with Nanoparticle for Local Chemotherapy of Tumors. <i>Pharmaceutical Research</i> , 2021, 38, 669-680.	3.5	5
46	Preclinical efficacy and safety evaluation of interleukin-6-knockdown CAR-T cells targeting at CD19. <i>Annals of Translational Medicine</i> , 2021, 9, 1713-1713.	1.7	5
47	CAR ⁺ therapy bridging to allogeneic HSCT provides durable molecular remission of Ph ⁺ mixed phenotype acute leukaemia with minimal residual disease. <i>British Journal of Haematology</i> , 2020, 191, e47-e49.	2.5	4
48	Quantitative radio-thin-layer chromatography and positron emission tomography studies for measuring streptavidin transduced chimeric antigen receptor T cells. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1182, 122944.	2.3	4
49	CD38-Directed CAR-T Cell Therapy: A Novel Immunotherapy Strategy for Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 34-34.	1.4	4
50	Immunoglobulin isotype switch after anti-BCMA CAR T-cell therapy for relapsed or refractory multiple myeloma. <i>Blood Advances</i> , 2022, 6, 293-296.	5.2	4
51	Cellular Kinetics of CD19 Chimeric Antigen Receptor T Cells in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma. <i>Blood</i> , 2019, 134, 4097-4097.	1.4	0
52	Successful application of PD-1 knockdown CLL-1 CAR-T therapy in two AML patients with post-transplant relapse and failure of anti-CD38 CAR-T cell treatment.. <i>American Journal of Cancer Research</i> , 2022, 12, 615-621.	1.4	0